Clinical and serum risk factors for coronary restenosis in patients with coronary artery disease

Aim. To study risk factors for coronary artery restenosis in a retrospective (identification of patients with restenosis) and prospective (biomarker analysis) study.

Material and methods. Patients with coronary stenosis were identified within 7 years after primary stenting. In 181 patients (67 — with coronary restenosis, 114 — without coronary restenosis), the clinical, demographic and serum biomarker profiles of patients were studied.

Results. The incidence of coronary restenosis was significantly higher in men (82,1% and 69,3%, p=0,047). Propensity score matching was used to balance the groups by sex, and as a result, a higher hereditary predisposition to cardiovascular diseases (p=0,024), sinus rhythm (p=0,020), low serum apolipoprotein A1 (p=0,048) and high alanine aminotransferase (p=0,023) were shown for the restenosis group.

Conclusion. Coronary artery restenosis was characterized by male sex, sinus rhythm, hereditary predisposition, increased alanine aminotransferase and decreased apolipoprotein A1.

1. Aoki J, Tanabe K, Hoye A, et al. Mechanisms of drug-eluting stent restenosis. Cardiovasc Intervention and Therapeutics. 2021;36(1):23-9. doi:10.1007/s12928-020-00734-7.

2. Enikeeva AM, Gazizova LYu, Gareeva DF, et al. Predictors of coronary in-stent restenosis. Bulletin of clinical medicine. 2023;6(4):83-9. (In Russ.) doi:10.20969/VSKM.2023.16(4).83-89.

3. Shames DV, Galyavich AS, Galeeva ZM, et al. The predictive value of preprocedural laboratory data in patients with coronary artery restenosis in various types of stents. Russian Journal of Cardiology. 2019;(3):54-9. (In Russ.) doi:10.15829/1560-4071-2019-3-54-59.

4. Omar A, Pendyala LK, Ormiston JA, et al. Review: Stent fracture in the drug-eluting stent era. Cardiovasc Revasc Med. 2016;17(6):404-11. doi:10.1016/j.carrev.2016.06.002.

5. Buccheri D, Piraino D, Andolina G, et al. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8(10): E1150-E1162. doi:10.21037/jtd.2016.10.93.

6. Mazaev VP, Komkov AA, Ryazanova SV. Clinical condition and cardiovascular risk factors displaying neoatherosclerosis in stented coronary arteries with developing restenosis. Cardiovascular Therapy and Prevention. 2016;15(5):64-9. (In Russ.) doi:10.15829/1728-8800-2016-5-64-69.

7. Shahsanaei F, Gharibzadeh A, Behrooj S, et al. A systematic review and bioinformatic study on clinical, paraclinical, and genetic factors predisposing to stent restenosis following percutaneous coronary intervention. BMC Cardiovasc Disord. 2024;14;24(1):304. doi:10.1186/s12872-024-03955-3.

8. Shlofmitz E, Case BC, Chen Y, et al. In-Stent Restenosis Classification: A MechanismBased Approach to the Treatment of Restenosis. Cardiovasc Revasc Med. 2021;33:62-7. doi:10.1016/j.carrev.2021.06.004.

9. Enikeeva AM, Gazizova LY, Buzaev IV, et al. Prediction of in-stent restenosis based on systematic and retrospective analyses. Global Translational Medicine. 2024;3(4):4957. doi:10.36922/gtm.4957.

10. Nayor M, Brown KJ, Vasan RS. The Molecular Basis of Predicting Atherosclerotic Cardiovascular Disease Risk. Circ Res. 2021;128(2):287-303. doi:10.1161/CIRCRESAHA.120.315890.

11. Wang Z, Sheng L, Gu H, et al. Rivaroxaban and Aspirin in Drug-Coated Balloon Angioplasty for Femoropopliteal In-Stent Restenosis: A Retrospective Cohort Study. Ann Vasc Surg. 2024;108:338-45. doi:10.1016/j.avsg.2024.05.031.

12. Wang X, Zhang M, Cheng J, et al. Association of serum apoA-I with in-stent restenosis in coronary heart disease. BMC Cardiovasc Disord. 2022;22(1):355. doi:10.1186/s12872-022-02762-y.

13. Cochran BJ, Ong KL, Manandhar B, et al. APOA1: a Protein with Multiple Therapeutic Functions. Curr Atheroscler Rep. 2021;23(3):11. doi:10.1007/s11883-021-00906-7.

14. Jamalinia M, Zare F, Noorizadeh K, et al. Systematic review with meta-analysis: Steatosis severity and subclinical atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Aliment Pharmacol Ther. 2024:445-58. doi:10.1111/apt.17869.